2,884,615 Shares Spring Bank Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 23rd, 2017 • Spring Bank Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Spring Bank Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom Cantor Fitzgerald & Co. and William Blair & Company, L.L.C. are acting as representatives (the “Representatives” or “you”) an aggregate of 2,884,615 shares (the “Firm Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) and, at the election of the Underwriters, subject to the terms and conditions stated herein, the Company shall issue and sell up to 432,692 additional shares (the “Option Shares”) of Common Stock. The Firm Shares and any Option Shares purchased pursuant Section 3 hereof are herein collectively called the “Securities.”
